Skip to Content
Merck
CN

C2235

CB 1954

solid

Synonym(s):

5-(1-Aziridinyl)-2,4-dinitrobenzamide, 5-(Aziridin-1-yl)-2,4-dinitrobenzamide

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

CAS Number:
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

CB 1954, solid

InChI

1S/C9H8N4O5/c10-9(14)5-3-7(11-1-2-11)8(13(17)18)4-6(5)12(15)16/h3-4H,1-2H2,(H2,10,14)

SMILES string

NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O

InChI key

WOCXQMCIOTUMJV-UHFFFAOYSA-N

assay

≥94% (HPLC)

form

solid

storage temp.

−20°C

Quality Level

Application

CB 1954 has been used in drug-induced ablation studies.

Biochem/physiol Actions

CB 1954 is an anticancer prodrug used in gene therapy research; activated by NAD(P)H quinone oxidoreductase 2.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew Christofferson et al.
Biochemical Society transactions, 37(Pt 2), 413-418 (2009-03-18)
NTR (nitroreductase NfsB from Escherichia coli) is a flavoprotein with broad substrate specificity, reducing nitroaromatics and quinones using either NADPH or NADH. One of its substrates is the prodrug CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide), which is converted into a cytotoxic agent; so NTR/CB1954
Thymopoiesis in mice depends on a Foxn1-positive thymic epithelial cell lineage
Corbeaux T, et al.
Proceedings of the National Academy of Sciences of the USA, 1-6 (2010)
Gareth A Prosser et al.
Biochemical pharmacology, 85(8), 1091-1103 (2013-02-13)
Two potentially complementary approaches to improve the anti-cancer strategy gene-directed enzyme prodrug therapy (GDEPT) are discovery of more efficient prodrug-activating enzymes, and development of more effective prodrugs. Here we demonstrate the utility of a flexible screening system based on the
S O Vass et al.
British journal of cancer, 100(12), 1903-1911 (2009-05-21)
Prodrug activation gene therapy is a developing approach to cancer treatment, whereby prodrug-activating enzymes are expressed in tumour cells. After administration of a non-toxic prodrug, its conversion to cytotoxic metabolites directly kills tumour cells expressing the activating enzyme, whereas the
Prashant Patel et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 17(7), 1292-1299 (2009-04-16)
We report a phase I/II clinical trial in prostate cancer (PCa) using direct intraprostatic injection of a replication defective adenovirus vector (CTL102) encoding bacterial nitroreductase (NTR) in conjunction with systemic prodrug CB1954. One group of patients with localized PCa scheduled

Articles

DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.

DNA损伤和修复机制对于维持DNA完整性至关重要。细胞DNA的损伤与突变、癌症发展等有关。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service